[go: up one dir, main page]

NO20000451L - Compounds that inhibit leukocyte adhesion mediated by VLA-4 - Google Patents

Compounds that inhibit leukocyte adhesion mediated by VLA-4

Info

Publication number
NO20000451L
NO20000451L NO20000451A NO20000451A NO20000451L NO 20000451 L NO20000451 L NO 20000451L NO 20000451 A NO20000451 A NO 20000451A NO 20000451 A NO20000451 A NO 20000451A NO 20000451 L NO20000451 L NO 20000451L
Authority
NO
Norway
Prior art keywords
compounds
vla
leukocyte adhesion
adhesion mediated
inhibit leukocyte
Prior art date
Application number
NO20000451A
Other languages
Norwegian (no)
Other versions
NO20000451D0 (en
Inventor
Michael S Dappen
Darren B Dressen
Francine S Grant
Michael A Pleiss
Cynthia Y Robinson
Dimitrios Sarantakis
Eugene D Thorsett
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of NO20000451D0 publication Critical patent/NO20000451D0/en
Publication of NO20000451L publication Critical patent/NO20000451L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Det er beskrevet forbindelser som binder VLA-4. Noen av disse forbindelsene inhiberer også leukocyttadhesjon og spesielt leukocyttadhesjon mediert av VLA-4. Slike forbindelser er nyttige for behandling av inflammatoriske sykdommer i en pattedyrpasient, for eksempel menneske, så som astma, Alzheimer's sykdom, aterosklerose, AIDS-demens, diabetes, inflammatorisk tarmsykdom, leddgikt, vevstransplantasjon, tumormetastase og myokardial ischemi. Forbindelsene kan også bli administrert for behandling av inflammatoriske hjernesykdommer så som multippel sklerose.Compounds that bind VLA-4 are described. Some of these compounds also inhibit leukocyte adhesion and especially leukocyte adhesion mediated by VLA-4. Such compounds are useful for the treatment of inflammatory diseases in a mammalian patient, such as human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds may also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

NO20000451A 1997-07-31 2000-01-28 Compounds that inhibit leukocyte adhesion mediated by VLA-4 NO20000451L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90441697A 1997-07-31 1997-07-31
PCT/US1998/015952 WO1999006433A1 (en) 1997-07-31 1998-07-31 Compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (2)

Publication Number Publication Date
NO20000451D0 NO20000451D0 (en) 2000-01-28
NO20000451L true NO20000451L (en) 2000-03-23

Family

ID=25419117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000451A NO20000451L (en) 1997-07-31 2000-01-28 Compounds that inhibit leukocyte adhesion mediated by VLA-4

Country Status (12)

Country Link
EP (1) EP1001973A1 (en)
JP (1) JP2001512136A (en)
KR (1) KR20010022423A (en)
CN (1) CN1265669A (en)
AU (1) AU8678698A (en)
BR (1) BR9811569A (en)
CA (1) CA2290746A1 (en)
HU (1) HUP0004529A3 (en)
IL (1) IL133641A0 (en)
NO (1) NO20000451L (en)
PL (1) PL338506A1 (en)
WO (1) WO1999006433A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
EP0998282A4 (en) * 1997-05-29 2000-08-30 Merck & Co Inc SULFAMIDES FOR USE AS CELL ADHESION INHIBITORS
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
DE69820614T2 (en) * 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough ANTI-INFLAMMATORY TYROSINE DERIVATIVES
DK0991619T3 (en) 1997-06-23 2003-12-29 Tanabe Seiyaku Co Inhibitors of alpha 4-beta 1-mediated cell adhesion
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
US6555562B1 (en) 1998-02-26 2003-04-29 Celltech R&D Limited Phenylalanine derivatives
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
ATE377003T1 (en) 1999-01-22 2007-11-15 Elan Pharm Inc COMPOUNDS THAT INHIBIT VLA-4-MEDIATED ADHESION OF LEUKOCYTES
IL143928A0 (en) 1999-01-22 2002-04-21 Elan Pharm Inc Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
GEP20053477B (en) 1999-08-13 2005-03-25 Biogen Inc Cell Adhesion Inhibitors and Pharmaceutical Compositions Containing Them
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
JP2003531141A (en) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド Enamine derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
JP2004502762A (en) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド Squaric acid derivatives as integrin antagonists containing bicyclic heteroaromatic rings
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
CA2460149A1 (en) * 2001-09-12 2003-03-27 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
FR2869904B1 (en) * 2004-05-07 2006-07-28 Fournier S A Sa Lab MODULATORS OF LXR RECEIVERS
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
JP5135235B2 (en) 2006-02-27 2013-02-06 エラン ファーマシューティカルズ，インコーポレイテッド Pyrimidinylsulfonamide compounds that inhibit leukocyte adhesion mediated by VAL-4
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (en) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド Human serum albumin linker and its conjugates
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679903B1 (en) * 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
WO1994007815A2 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
CA2150550A1 (en) * 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
JPH0873422A (en) * 1994-09-07 1996-03-19 Kdk Corp New amino acid ester and method for detecting leukocyte, esterase or protease
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
PL338506A1 (en) 2000-11-06
JP2001512136A (en) 2001-08-21
CN1265669A (en) 2000-09-06
EP1001973A1 (en) 2000-05-24
KR20010022423A (en) 2001-03-15
NO20000451D0 (en) 2000-01-28
IL133641A0 (en) 2001-04-30
HUP0004529A3 (en) 2001-05-28
WO1999006433A1 (en) 1999-02-11
AU8678698A (en) 1999-02-22
CA2290746A1 (en) 1999-02-11
HUP0004529A2 (en) 2001-04-28
BR9811569A (en) 2000-09-19

Similar Documents

Publication Publication Date Title
NO20000451L (en) Compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000414L (en) Benzyl compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000412L (en) Dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000452L (en) Sulfonylated dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000413L (en) Carbamyloxy compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000410L (en) Dipeptide and related compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000411L (en) 4-Amino-phenylalamine compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000450L (en) Substituted phenylalanine compounds that inhibit leukocyte adhesion mediated by VLA-4
MXPA01007335A (en) Acyl derivatives which treat vla-4 related disorders.
NO20070216L (en) Multivalent VLA-1 antagonists containing polymer halves
NO20043900L (en) Heterocyclic compounds that inhibit leukocyte adhesion mediated by integrins
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
EA200401561A1 (en) HETEROARRYLIC COMPOUNDS THAT INHIBIT MEDIATED ГР4-INTEGRINES leukocyte adhesion
IL190084A0 (en) Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application